Biotechnology Law Report

Papers
(The TQCC of Biotechnology Law Report is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Legal Governance of Human Gene Editing Technology: From Single Governance to Multiple Governance29
Is Cross-Border Transfer of Human Genetic Data an Impossible Mission?4
The Localization of Drug Patent Linkage System in China: Where Should It Go?3
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 13713
Selected Developments in Biotechnology Law and the Biotechnology Industry2
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?2
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.2
Amgen v. Sanofi : The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies2
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Sanho Corp. v. Kaijet Tech. Int’l Ltd., Inc1
Assessing Legal and Ethical Considerations for Processing Digital Medical Data in China: Framework, Issues, and Policy Recommendations1
A Review of Patent Regimes on Health Biotechnology Innovation in India1
Duke Univ. v. Sandoz Inc.1
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings1
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws1
Alnylam Pharms., Inc. v. Moderna, Inc.1
Agilent Techs., Inc. v. Synthego Corp.1
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1471
A 12th Year 101 Update—Diagnostic and DNA Claims Are Patent Eligible, but Pre- Mayo Patents May Continue to Fall1
Eye Therapies, LLC v. Slayback Pharma, LLC1
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China1
Astellas Pharma, Inc. v. Sandoz Inc. USA, Inc.1
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-191
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Hologic, Inc. v. Minerva Surgical, Inc.1
Recent Developments in FDA Regulatory Exclusivities1
Pac. Biosciences of California, Inc. v. Pers. Genomics Taiwan, Inc1
ImmunoGen, Inc. v. Stewart1
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption1
In re Entresto1
Vanda Pharms., Inc. v. United States Food & Drug Admin1
Incyte Corp. v. Sun Pharm. Indus., Ltd.1
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Regents of the Univ. of California v. Broad Inst., Inc.1
0.69279503822327